<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1755-5922</journal-id><journal-id journal-id-type="publisher-id">CDR</journal-id><journal-title-group><journal-title>Cardiovascular Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1755-5914</issn><issn pub-type="epub">1755-5922</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27506635</article-id><article-id pub-id-type="pmc">5108468</article-id><article-id pub-id-type="doi">10.1111/1755-5922.12213</article-id><article-id pub-id-type="publisher-id">CDR12213</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of fixed&#x02010;dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS&#x02010;ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)</article-title></title-group><contrib-group><contrib id="cdr12213-cr-0001" contrib-type="author"><name><surname>Kim</surname><given-names>Kyung&#x02010;Jin</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="cdr12213-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="cdr12213-cr-0002" contrib-type="author"><name><surname>Kim</surname><given-names>Sang&#x02010;Hyun</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="cdr12213-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="cdr12213-cr-0003" contrib-type="author"><name><surname>Yoon</surname><given-names>Young Won</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cdr12213-cr-0004" contrib-type="author"><name><surname>Rha</surname><given-names>Seung&#x02010;Woon</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cdr12213-cr-0005" contrib-type="author"><name><surname>Hong</surname><given-names>Soon&#x02010;Jun</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="cdr12213-cr-0006" contrib-type="author"><name><surname>Kwak</surname><given-names>Choong&#x02010;Hwan</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="cdr12213-cr-0007" contrib-type="author"><name><surname>Kim</surname><given-names>Weon</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cdr12213-cr-0008" contrib-type="author"><name><surname>Nam</surname><given-names>Chang&#x02010;Wook</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="cdr12213-cr-0009" contrib-type="author"><name><surname>Rhee</surname><given-names>Moo&#x02010;Yong</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="cdr12213-cr-0010" contrib-type="author"><name><surname>Park</surname><given-names>Tae&#x02010;Ho</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="cdr12213-cr-0011" contrib-type="author"><name><surname>Hong</surname><given-names>Taek&#x02010;Jong</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="cdr12213-cr-0012" contrib-type="author"><name><surname>Park</surname><given-names>Sungha</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="cdr12213-cr-0013" contrib-type="author"><name><surname>Ahn</surname><given-names>Youngkeun</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="cdr12213-cr-0014" contrib-type="author"><name><surname>Lee</surname><given-names>Namho</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="cdr12213-cr-0015" contrib-type="author"><name><surname>Jeon</surname><given-names>Hui&#x02010;Kyung</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="cdr12213-cr-0016" contrib-type="author"><name><surname>Jeon</surname><given-names>Dong&#x02010;Woon</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="cdr12213-cr-0017" contrib-type="author"><name><surname>Han</surname><given-names>Kyoo&#x02010;Rok</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0017">
<sup>17</sup>
</xref></contrib><contrib id="cdr12213-cr-0018" contrib-type="author"><name><surname>Moon</surname><given-names>Keon&#x02010;Woong</given-names></name><xref ref-type="aff" rid="cdr12213-aff-0018">
<sup>18</sup>
</xref></contrib><contrib id="cdr12213-cr-0019" contrib-type="author" corresp="yes"><name><surname>Chae</surname><given-names>In&#x02010;Ho</given-names></name><address><email>ihchae@snu.ac.kr</email></address><xref ref-type="aff" rid="cdr12213-aff-0019">
<sup>19</sup>
</xref></contrib><contrib id="cdr12213-cr-0020" contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Hyo&#x02010;soo</given-names></name><address><email>hyosoo@snu.ac.kr</email></address><xref ref-type="aff" rid="cdr12213-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cdr12213-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Seoul National University Hospital</named-content><institution>Seoul National University College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Boramae Medical Center</named-content><institution>Seoul National University College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Gangnam Severance Hospital</named-content><institution>Yonsei University College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Medical College</named-content><institution>Korea University</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Cardiovascular Center</named-content><institution>Korea University Anam Hospital</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Cardiovascular Center</named-content><institution>Gyeongsang National University Hospital</institution><named-content content-type="city">Jinju</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Cardiovascular Department of Internal Medicine</named-content><institution>Kyung Hee University Hospital</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Dongsan Hospital</named-content><institution>Keimyung University</institution><named-content content-type="city">Gyeongju</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Cardiovascular Center</named-content><institution>Dongguk University Ilsan Hospital</institution><named-content content-type="city">Goyang</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0010"><label><sup>10</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Cardiology Division</named-content><institution>Dong&#x02010;A University Hospital</institution><named-content content-type="city">Busan</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0011"><label><sup>11</sup></label><institution>Pusan National University Hospital</institution><named-content content-type="city">Busan</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0012"><label><sup>12</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Severance Cardiovascular Hospital</named-content><institution>Yonsei University College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0013"><label><sup>13</sup></label><named-content content-type="organisation-division">Department of Cardiology</named-content><named-content content-type="organisation-division">Heart Center</named-content><institution>Chonnam National University Hospital</institution><named-content content-type="city">Gwangju</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0014"><label><sup>14</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><named-content content-type="organisation-division">Kangnam Sacred Heart Hospital</named-content><institution>Hallym University College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0015"><label><sup>15</sup></label><named-content content-type="organisation-division">Department of Cardiovascular</named-content><named-content content-type="organisation-division">Uijeongbu, Mary's Hospital</named-content><institution>The Catholic University of Korea</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0016"><label><sup>16</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>NHIC Ilsan Hospital</institution><named-content content-type="city">Goyang</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0017"><label><sup>17</sup></label><named-content content-type="organisation-division">Kangdong Sacred Heart Hospital</named-content><named-content content-type="organisation-division">College of Medicine</named-content><institution>Hallym University</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0018"><label><sup>18</sup></label><named-content content-type="organisation-division">Cardiology Division</named-content><named-content content-type="organisation-division">St. Vincent's Hospital</named-content><institution>The Catholic University of Korea</institution><named-content content-type="city">Suwon</named-content><country country="KP">Korea</country></aff><aff id="cdr12213-aff-0019"><label><sup>19</sup></label><named-content content-type="organisation-division">Cardiovascular Center</named-content><institution>Seoul National University Bundang Hospital</institution><named-content content-type="city">Seongnam</named-content><country country="KP">Korea</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
I. H. Chae, Department of Internal Medicine, Seoul National University Bundang Hospital, Bundang&#x02010;gu, Seongnam City, Gyeonggi&#x02010;do, Korea<break/>
Email: <email>ihchae@snu.ac.kr</email><break/>
and<break/>
H. S. Kim, Department of Internal Medicine, Seoul National University College of Medicine, Jongro&#x02010;gu, Seoul, Korea<break/>
Email: <email>hyosoo@snu.ac.kr</email><break/></corresp><fn id="cdr12213-note-0001"><label>&#x02020;</label><p>Co&#x02010;first authors: K. J. Kim and S. H. Kim</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><volume>34</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/cdr.2016.34.issue-5</issue-id><fpage>371</fpage><lpage>382</lpage><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors Cardiovascular Therapeutics Published by John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CDR-34-371.pdf"/><abstract id="cdr12213-abs-0001"><title>Summary</title><sec id="cdr12213-sec-0001"><title>Aim</title><p>We aimed to compare the effects of fixed&#x02010;dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS).</p></sec><sec id="cdr12213-sec-0002"><title>Method</title><p>This multicenter eight&#x02010;week randomized double&#x02010;blind phase III study evaluated the safety and efficacy of fixed&#x02010;dose combinations of ezetimibe 10&#x000a0;mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia. Four hundred and seven patients with primary hypercholesterolemia who required lipid&#x02010;lowering treatment according to the ATP III guideline were randomized to one of the following six treatments for 8&#x000a0;weeks: fixed&#x02010;dose combinations with ezetimibe 10&#x000a0;mg daily plus rosuvastatin (5, 10, or 20&#x000a0;mg daily) or rosuvastatin alone (5, 10, or 20&#x000a0;mg daily).</p></sec><sec id="cdr12213-sec-0003"><title>Results</title><p>Fixed&#x02010;dose combination of ezetimibe plus rosuvastatin significantly reduced LDL cholesterol, total cholesterol, and triglyceride levels compared with rosuvastatin alone. Depending on the rosuvastatin dose, these fixed&#x02010;dose combinations of ezetimibe plus rosuvastatin provided LDL cholesterol, total cholesterol, and triglyceride reductions of 56%&#x02013;63%, 37%&#x02013;43%, and 19%&#x02013;24%, respectively. Moreover, the effect of combination treatment on cholesterol levels was more pronounced in patients with DM or MetS than in non&#x02010;DM or non&#x02010;MetS patients, respectively, whereas the effect of rosuvastatin alone did not differ between DM vs non&#x02010;DM or MetS vs non&#x02010;MetS patients.</p></sec><sec id="cdr12213-sec-0004"><title>Conclusion</title><p>Fixed&#x02010;dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels. Moreover, the reduction rate was greater in patients with DM or MetS.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cdr12213-kwd-0001">Cholesterol</kwd><kwd id="cdr12213-kwd-0002">Diabetes mellitus</kwd><kwd id="cdr12213-kwd-0003">Ezetimibe</kwd><kwd id="cdr12213-kwd-0004">Hypercholesterolemia</kwd><kwd id="cdr12213-kwd-0005">Metabolic syndrome</kwd><kwd id="cdr12213-kwd-0006">Rosuvastatin</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Health and Welfare (MHW)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Korea Health Industry Development Institute (KHIDI)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Korea Health Technology R&#x00026;D Project</funding-source><award-id>HI14C1277</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="5"/><page-count count="12"/><word-count count="8598"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cdr12213</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.7 mode:remove_FC converted:14.11.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cdr12213-ntgp-0001"><fn id="cdr12213-note-1002"><p>Clinical trial registration number: NCT02205606 (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>)</p></fn></fn-group></notes></front><body><sec id="cdr12213-sec-0005"><label>1</label><title>Introduction</title><p>Cardiovascular disease is a leading cause of significant morbidity and mortality. Dyslipidemia is a major modifiable risk factor for the development of cardiovascular disease, and one of the cornerstones in the prevention of cardiovascular events is a reduction in the level of low&#x02010;density lipoprotein (LDL) cholesterol.<xref rid="cdr12213-bib-0001" ref-type="ref">1</xref>, <xref rid="cdr12213-bib-0002" ref-type="ref">2</xref>
</p><p>The most effective class of drugs for lowering the serum LDL cholesterol levels is 3&#x02010;hydroxy&#x02010;3&#x02010;methylglutaryl coenzyme reductase inhibitors, also known as statins.<xref rid="cdr12213-bib-0003" ref-type="ref">3</xref> Aggressive therapy to lower LDL cholesterol levels with various statins or the same statin at various doses has been reported to be associated with reduced rates of cardiovascular events.<xref rid="cdr12213-bib-0004" ref-type="ref">4</xref>, <xref rid="cdr12213-bib-0005" ref-type="ref">5</xref>, <xref rid="cdr12213-bib-0006" ref-type="ref">6</xref>, <xref rid="cdr12213-bib-0007" ref-type="ref">7</xref>, <xref rid="cdr12213-bib-0008" ref-type="ref">8</xref> However, despite the efficacy of statins having been established, the number of patients who achieve the lipid targets is still suboptimal,<xref rid="cdr12213-bib-0009" ref-type="ref">9</xref>, <xref rid="cdr12213-bib-0010" ref-type="ref">10</xref> and increasing the dose of statin leads only to a limited reduction in the LDL cholesterol levels and is associated with a higher incidence of side effects.<xref rid="cdr12213-bib-0011" ref-type="ref">11</xref>, <xref rid="cdr12213-bib-0012" ref-type="ref">12</xref> Therefore, further reducing the LDL cholesterol levels to the target goal using novel compounds or combination drug therapy with currently available drugs is of interest.<xref rid="cdr12213-bib-0008" ref-type="ref">8</xref>, <xref rid="cdr12213-bib-0013" ref-type="ref">13</xref>
</p><p>Ezetimibe is a novel cholesterol absorption inhibitor that prevents cholesterol absorption by binding to the Niemann&#x02013;Pick C1&#x02010;like 1 (NPC1L1) protein.<xref rid="cdr12213-bib-0010" ref-type="ref">10</xref>, <xref rid="cdr12213-bib-0014" ref-type="ref">14</xref> NPC1L1 is an intestinal cholesterol transporter,<xref rid="cdr12213-bib-0015" ref-type="ref">15</xref> expressed in the brush border membrane of enterocytes in the small intestine.<xref rid="cdr12213-bib-0016" ref-type="ref">16</xref> Moreover, the NPC1L1 transporter is also expressed in the liver, where it reabsorbs cholesterol from bile.<xref rid="cdr12213-bib-0017" ref-type="ref">17</xref> Hence, ezetimibe decreases the plasma cholesterol levels by preventing cholesterol from being taken up by intestinal enterocytes and absorbed from the intestinal lumen and also restoring biliary cholesterol excretion.<xref rid="cdr12213-bib-0015" ref-type="ref">15</xref>, <xref rid="cdr12213-bib-0016" ref-type="ref">16</xref>, <xref rid="cdr12213-bib-0017" ref-type="ref">17</xref>, <xref rid="cdr12213-bib-0018" ref-type="ref">18</xref>
</p><p>Previous studies have reported the efficacy of combined therapy with ezetimibe and variable statins, with resulting reductions in the LDL cholesterol levels of 12%&#x02013;19%.<xref rid="cdr12213-bib-0010" ref-type="ref">10</xref>, <xref rid="cdr12213-bib-0013" ref-type="ref">13</xref>, <xref rid="cdr12213-bib-0019" ref-type="ref">19</xref>, <xref rid="cdr12213-bib-0020" ref-type="ref">20</xref> Moreover, the IMPROVE&#x02010;IT study recently demonstrated that the addition of ezetimibe to statin therapy resulted in a significantly lower risk of cardiovascular events. Therefore, combined therapy with ezetimibe and statins may achieve not only incremental reductions in the LDL cholesterol levels, but may also improve the cardiovascular outcomes.<xref rid="cdr12213-bib-0021" ref-type="ref">21</xref>
</p><p>To date, a fixed&#x02010;dose combination of ezetimibe and rosuvastatin has not yet been developed and tested. Therefore, the objective of this study was to compare the LDL cholesterol&#x02010;lowering effects of fixed&#x02010;dose combinations of ezetimibe 10&#x000a0;mg plus rosuvastatin 5, 10, or 20&#x000a0;mg, as compared with rosuvastatin alone in patients with primary hypercholesterolemia. We also performed a subgroup analysis of safety and efficacy in patients with diabetes mellitus and metabolic syndrome.</p></sec><sec id="cdr12213-sec-0006"><label>2</label><title>Methods</title><sec id="cdr12213-sec-0007"><label>2.1</label><title>Study design</title><p>The present Multicenter Randomized Study of ROsuvastatin and eZEtimibe (MRS&#x02010;ROZE) was an eight&#x02010;week, double&#x02010;blind, parallel&#x02010;group study conducted in 19 centers in South Korea (clinical trials.gov identifier: NCT002205606) from June 24, 2014, to September 21, 2015. The study protocol was approved by institutional review boards at each participating center, and all study participants provided written informed consent. Subjects with primary hypercholesterolemia and age over 19&#x000a0;years were screened. At the first visit, subjects with initial levels of LDL cholesterol &#x02264;250&#x000a0;mg/dL and triglyceride (TG) &#x0003c;400&#x000a0;mg/dL were selected. These patients discontinued lipid&#x02010;lowering therapy and followed the National Cholesterol Education Program Adult Treatment Panel III (ATP III) Therapeutic Lifestyle Changes <xref rid="cdr12213-bib-0022" ref-type="ref">22</xref> diet during a four&#x02010;week dietary lead&#x02010;in period. After the lead&#x02010;in period, the levels of LDL cholesterol and TG were assessed again and the patients who required lipid&#x02010;lowering treatment according to the ATP III guidelines were finally enrolled in the study. Eligible patients were also required to have LDL cholesterol levels &#x02264;250&#x000a0;mg/dL and TG levels &#x0003c;400&#x000a0;mg/dL at the second visit. The main exclusion criteria included (1) history of significant statin and/or ezetimibe&#x02010;induced myopathy or rhabdomyolysis; (2) history of serious hypersensitivity reaction to rosuvastatin or ezetimibe; (3) history of unstable angina, myocardial infarction, myocardial revascularization, coronary artery bypass surgery, transient ischemic attack, or stroke within 3&#x000a0;months of the rosuvastatin run&#x02010;in period; (4) severe congestive heart failure (New York Heart Association III or IV); (5) current active liver disease (alanine aminotransferase and/or aspartate aminotransferase &#x0003e;3 times the upper limit of normal); (6) serum creatinine &#x02265;3 times the upper limit of normal; (7) creatine kinase levels &#x0003e;5 times the upper limit of normal; (8) the use of prohibited concomitant therapies; (9) history of malignancy within the last 5&#x000a0;years; (10) disorders of the digestive system, including galactose intolerance, Lapp lactase deficiency, or glucose&#x02013;galactose malabsorption, which might limit the study evaluation; and (11) women who were of childbearing potential without contraception, pregnant, or breastfeeding.</p><p>Participating subjects were centrally randomized in a 1:1 ratio to either fixed&#x02010;dose combinations of ezetimibe 10&#x000a0;mg daily plus rosuvastatin or rosuvastatin alone. Specifically, eligible subjects were randomly assigned to one of the following six treatments for 8&#x000a0;weeks: fixed&#x02010;dose combinations of ezetimibe 10&#x000a0;mg daily plus rosuvastatin (5, 10, or 20&#x000a0;mg daily) (combo therapy) or rosuvastatin alone (5, 10, or 20&#x000a0;mg daily) (monotherapy). Randomization was performed via a web&#x02010;based online randomization system. All study personnel including the investigators, study site personnel, participants, monitors, and central laboratory personnel were blinded to the treatment allocation throughout the study.</p></sec><sec id="cdr12213-sec-0008"><label>2.2</label><title>Efficacy and safety assessments</title><p>The primary efficacy endpoint was the percentage change from baseline in LDL cholesterol in the overall study population. Secondary efficacy endpoints included the percent changes from baseline in other lipids, including total cholesterol, high&#x02010;density lipoprotein (HDL) cholesterol, TG, non&#x02010;HDL cholesterol, apolipoprotein A1, and apolipoprotein B. Another secondary efficacy endpoint was the percentage of patients reaching prespecified goals of LDL cholesterol levels depending on coronary heart disease (CHD) risk factors according to the ATP III guideline. Briefly, the LDL cholesterol goals for the three risk levels are as follows: (1) patients with coronary heart disease (CHD) and CHD risk equivalent, LDL cholesterol &#x0003c;100&#x000a0;mg/dL; (2) patients with multiple (&#x02265;2) risk factors, LDL cholesterol &#x0003c;130&#x000a0;mg/dL, except for patients with a 10&#x02010;year risk &#x0003e;20%, for whom the goal is LDL cholesterol &#x0003c;100&#x000a0;mg/dL; and (3) patients with no or one risk factor, LDL cholesterol &#x0003c;160&#x000a0;mg/dL.<xref rid="cdr12213-bib-0001" ref-type="ref">1</xref> The efficacy analyses included the full analysis set population.</p><p>Additionally, subgroup analyses of subjects with diabetes mellitus (DM) or metabolic syndrome (MetS) were performed. The percentage changes from baseline to 8&#x000a0;weeks in LDL cholesterol and other lipids in the prespecified subgroups were analyzed. The definition of DM was a fasting serum glucose level &#x02265;126&#x000a0;mg/dL or HbA1c &#x02265;6.5% <xref rid="cdr12213-bib-0023" ref-type="ref">23</xref> or self&#x02010;reported use of antihyperglycemic medications. The definition of MetS was the presence of at least three of the following five factors: elevated blood pressure (systolic blood pressure &#x02265;130&#x000a0;mm&#x000a0;Hg or diastolic blood pressure &#x02265;85&#x000a0;mm&#x000a0;Hg), abdominal obesity (waist circumference &#x02265;90&#x000a0;cm in men, &#x02265;80&#x000a0;cm in women), elevated TG (&#x02265;150&#x000a0;mg/dL), reduced HDL cholesterol (&#x0003c;40&#x000a0;mg/dL in men, &#x0003c;50&#x000a0;mg/dL in women), and elevated fasting glucose (&#x02265;100&#x000a0;mg/dL or receiving treatment for elevated glucose).<xref rid="cdr12213-bib-0024" ref-type="ref">24</xref>
</p><p>Safety was evaluated by monitoring of clinical adverse events (AEs) and laboratory AEs using the all&#x02010;patients&#x02010;as&#x02010;treated population by the investigators&#x02019; observations, patient&#x02010;reported adverse symptoms/signs, and various laboratory tests. The investigators of the individual centers rated the AEs in terms of their relationship to the study medication (definitely, probably, possibly, and probably not related), seriousness (death or life&#x02010;threatening events, prolonged hospitalization, and/or disability/incapacitation), and intensity (mild, moderate, or severe), while blinded to the treatment allocation.</p></sec><sec id="cdr12213-sec-0009"><label>2.3</label><title>Statistical analysis</title><p>The target enrollment was 396 patients to result in 354 assessable patients for the primary endpoint. With this number of patients, assuming a within&#x02010;group standard deviation of 15%, there was 90% power to detect 9% difference between the treatment groups (&#x003b1;=.05, two&#x02010;sided). The significance of differences in the baseline characteristics between the combo therapy and monotherapy groups was assessed by Student's <italic>t</italic>&#x02010;test for continuous variables and the chi&#x02010;square test (Fisher's exact test) for categorical variables. The percentage changes in LDL cholesterol and other lipids between the groups were evaluated using analysis of covariance with terms for the CHD risk factors according to the ATP III guideline and baseline levels of lipid parameters, resulting in the least&#x02010;squares mean for each treatment. The significance of another key secondary endpoint, the difference in percentage of patients reaching the prespecified goals of LDL cholesterol levels according to the ATP III guideline, was estimated using the Cochran&#x02013;Mantel&#x02013;Haenszel test for pooled data and Fisher's exact test for each risk group. For all analyses, a <italic>P</italic> value &#x0003c;.05 was considered statistically significant. All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).</p></sec></sec><sec id="cdr12213-sec-0010"><label>3</label><title>Results</title><sec id="cdr12213-sec-0011"><label>3.1</label><title>Baseline characteristics</title><p>Of the 583 screened patients who entered the dietary lead&#x02010;in period, 412 were randomly assigned the study drug(s) and 407 patients were analyzed (Figure&#x000a0;<xref rid="cdr12213-fig-0001" ref-type="fig">1</xref>). A total of 204 patients (50%) received rosuvastatin alone (rosuvastatin 5, 10, or 20&#x000a0;mg daily) and 203 patients (50%) received fixed&#x02010;dose combination of rosuvastatin and ezetimibe [ezetimibe 10&#x000a0;mg daily plus rosuvastatin (5, 10, or 20&#x000a0;mg daily)]). Overall, 3.9% and 2.5% of subjects who received combo therapy and monotherapy, respectively, discontinued the study treatment due to the withdrawal of consent. The compliance was similar between the treatment groups; at the end of the study, the compliance was 97% in the rosuvastatin&#x02010;alone group and 96% in the combo therapy group.</p><fig fig-type="Figure" xml:lang="en" id="cdr12213-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Participant distribution. FAS, full analysis set; E10, ezetimibe 10&#x000a0;mg; R5, rosuvastatin 5&#x000a0;mg; R10, rosuvastatin 10&#x000a0;mg; R20, rosuvastatin 20&#x000a0;mg</p></caption><graphic id="nlm-graphic-1" xlink:href="CDR-34-371-g001"/></fig><p>The baseline characteristics were similar between the treatment groups in terms of demographic and clinical data (Table&#x000a0;<xref rid="cdr12213-tbl-0001" ref-type="table-wrap">1</xref>). Overall, the mean age was 64&#x000a0;years and 56% of patients were men. A total of 135 (33%) patients had DM, 135 (33%) patients had MetS, 77 (19%) patients had both DM and MetS, 288 (70%) had hypertension, and 337 (82%) had a history of coronary artery disease.</p><table-wrap id="cdr12213-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics (full analysis set population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">R (n=204)</th><th align="center" valign="top" rowspan="1" colspan="1">R+E (n=203)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Demographic</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.3&#x000b1;9.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.2&#x000b1;7.9</td><td align="char" char="." rowspan="1" colspan="1">.951</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">118 (57.8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">113 (55.7)</td><td align="char" char="." rowspan="1" colspan="1">.657</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.2&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.7&#x000b1;2.9</td><td align="char" char="." rowspan="1" colspan="1">.191</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Family history of CHD, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">22 (10.8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28 (13.8)</td><td align="char" char="." rowspan="1" colspan="1">.355</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current smoker, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28 (13.7)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">35 (17.3)</td><td align="char" char="." rowspan="1" colspan="1">.612</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">72 (35.3)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63 (31.3)</td><td align="char" char="." rowspan="1" colspan="1">.362</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Metabolic syndrome, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 (33.8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">66 (32.5)</td><td align="char" char="." rowspan="1" colspan="1">.833</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes and metabolic syndrome, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">40 (19.6)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">37 (18.2)</td><td align="char" char="." rowspan="1" colspan="1">.292</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">141 (69.1)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">147 (72.4)</td><td align="char" char="." rowspan="1" colspan="1">.465</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Past history of CHD, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">166 (81.4)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">171 (84.2)</td><td align="char" char="." rowspan="1" colspan="1">.444</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Washout information, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Statin</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">119 (58.3)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">111 (54.7)</td><td align="char" char="." rowspan="1" colspan="1">.457</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fibrate</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1 (0.5)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2 (1.0)</td><td align="char" char="." rowspan="1" colspan="1">.623</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Bile acid sequestrant</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0 (0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0 (0)</td><td align="char" char="." rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nicotinic acid</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0 (0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2 (1.0)</td><td align="char" char="." rowspan="1" colspan="1">.248</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Combination (statin + other)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16 (7.8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14 (6.9)</td><td align="char" char="." rowspan="1" colspan="1">.715</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Other</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3 (1.5)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9 (4.4)</td><td align="char" char="." rowspan="1" colspan="1">.077</td></tr><tr><td align="left" colspan="4" rowspan="1">Baseline lipid profile &#x000b1; SD</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL cholesterol, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">147.7&#x000b1;30.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">147.7&#x000b1;31.3</td><td align="char" char="." rowspan="1" colspan="1">.993</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">221.2&#x000b1;35.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">221.0&#x000b1;36.5</td><td align="char" char="." rowspan="1" colspan="1">.975</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">152.7&#x000b1;73.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">152.5&#x000b1;69.4</td><td align="char" char="." rowspan="1" colspan="1">.977</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL cholesterol, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">50.1&#x000b1;11.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">49.6&#x000b1;12.9</td><td align="char" char="." rowspan="1" colspan="1">.646</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;HDL cholesterol, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">171.0&#x000b1;35.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">171.5&#x000b1;35.2</td><td align="char" char="." rowspan="1" colspan="1">.897</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein B, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">124.1&#x000b1;23.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">124.1&#x000b1;23.3</td><td align="char" char="." rowspan="1" colspan="1">.989</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein A1, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">142.6&#x000b1;22.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">142.1&#x000b1;24.5</td><td align="char" char="." rowspan="1" colspan="1">.828</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipoprotein(a), mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">39.3&#x000b1;34.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38.2&#x000b1;35.3</td><td align="char" char="." rowspan="1" colspan="1">.765</td></tr></tbody></table><table-wrap-foot><fn id="cdr12213-note-0004"><p>Variables are presented as mean &#x000b1; SD or n (%); SD, standard deviation; BMI, body mass index; CHD, coronary heart disease; LDL, low&#x02010;density lipoprotein; HDL, high&#x02010;density lipoprotein; R, rosuvastatin; E, ezetimibe.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The baseline lipid parameters were generally similar between the treatment groups (Table&#x000a0;<xref rid="cdr12213-tbl-0001" ref-type="table-wrap">1</xref>). Overall, the mean LDL cholesterol levels were 147.7&#x000b1;31.3&#x000a0;mg/dL, which were similar between the combo therapy and monotherapy groups (147.7&#x000b1;31.3&#x000a0;mg/dL vs 147.7&#x000b1;30.6&#x000a0;mg/dL, <italic>P</italic>=.993). Other lipids including total cholesterol, TG, HDL cholesterol, non&#x02010;HDL cholesterol, apolipoprotein B, and apolipoprotein A1 did not differ between the two treatment groups (Table&#x000a0;<xref rid="cdr12213-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="cdr12213-sec-0012"><label>3.2</label><title>Efficacy</title><p>The fixed&#x02010;dose combination of rosuvastatin and ezetimibe achieved significantly greater reductions in LDL cholesterol levels than rosuvastatin alone in the pooled data analysis, as well as in the comparisons for each rosuvastatin dose at weeks 4 and 8 (Figure&#x000a0;<xref rid="cdr12213-fig-0002" ref-type="fig">2</xref>) (pooled data: &#x02212;88.3&#x000a0;mg/dL vs &#x02212;74.4&#x000a0;mg/dL at week 8; the difference between the two groups: &#x02212;13.9&#x000a0;mg/dL) (least&#x02010;squares mean percent change: &#x02212;59.1% vs &#x02212;49.4% at week 8, <italic>P</italic>&#x0003c;.001, Table&#x000a0;<xref rid="cdr12213-tbl-0002" ref-type="table-wrap">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="cdr12213-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>LDL cholesterol levels at baseline and after treatment. Bars represent standard errors; LDL, low&#x02010;density lipoprotein; E, ezetimibe 10&#x000a0;mg; R5, rosuvastatin 5&#x000a0;mg; R10, rosuvastatin 10&#x000a0;mg; R20, rosuvastatin 20&#x000a0;mg</p></caption><graphic id="nlm-graphic-3" xlink:href="CDR-34-371-g002"/></fig><table-wrap id="cdr12213-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Percentage change in lipid parameters from baseline at weeks 4 and 8 (full analysis set population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">R (n=204)</th><th align="center" valign="top" rowspan="1" colspan="1">R+E (n=203)</th><th align="center" valign="top" rowspan="1" colspan="1">Difference</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI for difference</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Week 4</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">%&#x000b1;SEM</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;50.0&#x000b1;1.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;60.9&#x000b1;1.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;10.9&#x000b1;1.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;13.8, &#x02212;8.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;33.0&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;40.8&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.7&#x000b1;1.1</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;9.9, &#x02212;5.6</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;13.9&#x000b1;3.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;24.4&#x000b1;3.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;10.5&#x000b1;2.9</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;16.2, &#x02212;4.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.4&#x000b1;2.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14.9&#x000b1;2.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.5&#x000b1;1.8</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.1, 7.0</td><td align="char" char="." rowspan="1" colspan="1">.054</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;46.1&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;56.6&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;10.6&#x000b1;1.4</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;13.3, &#x02212;7.9</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein B</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;43.4&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;51.3&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.9&#x000b1;1.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;10.3, &#x02212;5.5</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein A1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.7&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9.0&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3&#x000b1;1.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.1, 3.6</td><td align="char" char="." rowspan="1" colspan="1">.290</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipoprotein(a)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.5&#x000b1;7.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">21.9&#x000b1;6.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9.4&#x000b1;6.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;2.4, 21.3</td><td align="char" char="." rowspan="1" colspan="1">.117</td></tr><tr><td align="left" colspan="6" rowspan="1">Week 8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;49.4&#x000b1;1.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;59.1&#x000b1;1.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;9.7&#x000b1;1.6</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;12.8, &#x02212;6.6</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;32.9&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;39.6&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.7&#x000b1;1.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;9.0, &#x02212;4.4</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;13.4&#x000b1;3.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;22.7&#x000b1;3.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;9.3&#x000b1;3.1</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;15.4, &#x02212;3.3</td><td align="char" char="." rowspan="1" colspan="1">.003</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.7&#x000b1;2.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14.1&#x000b1;2.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.5&#x000b1;1.8</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.1, 6.0</td><td align="char" char="." rowspan="1" colspan="1">.171</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;45.8&#x000b1;1.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;54.9&#x000b1;1.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;9.0&#x000b1;1.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.9, &#x02212;6.1</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein B</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;42.8&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;50.0&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.3&#x000b1;1.3</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;9.8, &#x02212;4.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein A1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.2&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9.1&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.8&#x000b1;1.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.5, 3.2</td><td align="char" char="." rowspan="1" colspan="1">.476</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipoprotein(a)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14.1&#x000b1;7.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.0&#x000b1;7.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10.9&#x000b1;6.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;2.0, 23.8</td><td align="char" char="." rowspan="1" colspan="1">.096</td></tr></tbody></table><table-wrap-foot><fn id="cdr12213-note-0005"><p>Variables are presented as the least&#x02010;squares means &#x000b1; SEM; SEM, standard error of the mean; CI, confidence interval; LDL, low&#x02010;density lipoprotein; HDL, high&#x02010;density lipoprotein; R, rosuvastatin; E, ezetimibe.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>In terms of the other lipids, including total cholesterol, TG, non&#x02010;HDL cholesterol, and apolipoprotein B, combo therapy showed significantly greater percent reductions than monotherapy in the pooled data analysis, as well as in the comparisons for each rosuvastatin dose, at both weeks 4 and 8 (Table&#x000a0;<xref rid="cdr12213-tbl-0002" ref-type="table-wrap">2</xref>, Figure&#x000a0;<xref rid="cdr12213-fig-0003" ref-type="fig">3</xref>). The HDL cholesterol levels increased in both treatment groups, with no difference observed between the two groups (Table&#x000a0;<xref rid="cdr12213-tbl-0002" ref-type="table-wrap">2</xref>, Figure&#x000a0;<xref rid="cdr12213-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="cdr12213-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Comparison of the percent changes in LDL cholesterol, TG, and HDL cholesterol between monotherapy and combo therapy for 8&#x000a0;wk: pooled data and data of the three different doses. Bars represent standard errors; LDL, low&#x02010;density lipoprotein; TG, triglyceride; HDL, high&#x02010;density lipoprotein; LS means, least&#x02010;squares means; R, rosuvastatin (pooled); E, ezetimibe 10&#x000a0;mg; R5, rosuvastatin 5&#x000a0;mg; R10, rosuvastatin 10&#x000a0;mg; R20, rosuvastatin 20&#x000a0;mg. *<italic>P</italic>&#x0003c;.05 for the specified between&#x02010;treatment difference</p></caption><graphic id="nlm-graphic-5" xlink:href="CDR-34-371-g003"/></fig><p>The difference in LDL cholesterol reduction between the combo therapy and monotherapy was significant and greater in patients with DM (n=135, 33%) than in non&#x02010;DM patients (patients with DM: &#x02212;64.2% vs &#x02212;50.2%, difference: &#x02212;14.0%, <italic>P</italic>&#x0003c;.001; non&#x02010;DM patients: &#x02212;57.7% vs &#x02212;49.8%, difference: &#x02212;7.9%, <italic>P</italic>&#x0003c;.001; at 8&#x000a0;week; Table&#x000a0;<xref rid="cdr12213-tbl-0003" ref-type="table-wrap">3</xref>, Figure&#x000a0;<xref rid="cdr12213-fig-0004" ref-type="fig">4</xref>). In other words, the potency of the combo therapy was greater in patients with DM than in non&#x02010;DM patients, whereas the potency of the monotherapy was the same in both patients with DM and non&#x02010;DM patients (combo therapy: patients with DM 64.2% vs non&#x02010;DM patients &#x02212;57.7%, <italic>P</italic>=.008). These results were similar to those observed for other lipids, including total cholesterol, non&#x02010;HDL cholesterol, and apolipoprotein B (Table&#x000a0;<xref rid="cdr12213-tbl-0003" ref-type="table-wrap">3</xref>, Figure&#x000a0;<xref rid="cdr12213-fig-0004" ref-type="fig">4</xref>). The TG levels showed greater decreases with combo therapy than with monotherapy, and these decreases were comparable between patients with DM and non&#x02010;DM patients (Figure S1). No significant differences were observed in HDL cholesterol and apolipoprotein A (Table&#x000a0;<xref rid="cdr12213-tbl-0003" ref-type="table-wrap">3</xref>, Figure S1).</p><table-wrap id="cdr12213-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Percentage changes in lipid parameters from baseline to week 8 (full analysis set population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Diabetes</th><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Nondiabetes</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">R(n=72)</th><th align="center" valign="top" rowspan="1" colspan="1">R+E(n=63)</th><th align="center" valign="top" rowspan="1" colspan="1">Difference</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI of difference</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">R(n=132)</th><th align="center" valign="top" rowspan="1" colspan="1">R+E(n=140)</th><th align="center" valign="top" rowspan="1" colspan="1">Difference</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI of difference</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="11" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">66.1&#x000b1;7.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.9&#x000b1;7.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.2&#x000b1;7.8</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.372</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63.2&#x000b1;9.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63.9&#x000b1;8.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.6&#x000b1;8.9</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.555</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">44 (61.1)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38 (60.3)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.925</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">74 (56.1)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">75 (53.6)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.680</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.0&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.8&#x000b1;3.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.2&#x000b1;3.0</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.689</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.7&#x000b1;2.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.3&#x000b1;2.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.4&#x000b1;2.7</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.263</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Average R dose, mg<xref ref-type="fn" rid="cdr12213-note-0007">a</xref>
</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.6&#x000b1;6.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.1&#x000b1;6.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.8&#x000b1;6.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.1&#x000b1;6.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Week 8</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">%&#x000b1;SEM</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">%&#x000b1;SEM</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;50.2&#x000b1;1.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;64.2&#x000b1;2.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;14.0&#x000b1;2.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;19.3, &#x02212;8.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;49.8&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;57.7&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.9&#x000b1;1.9</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.7, &#x02212;4.1</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">R5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;42.3&#x000b1;4.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;63.6&#x000b1;4.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;21.3&#x000b1;6.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;34.4, &#x02212;8.2</td><td align="char" char="." rowspan="1" colspan="1">.002</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;42.0&#x000b1;2.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;53.1&#x000b1;1.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.0&#x000b1;2.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;16.5, 5.6</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">R10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;52.0&#x000b1;2.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;63.9&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;12.0&#x000b1;3.6</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;19.3, &#x02212;4.8</td><td align="char" char="." rowspan="1" colspan="1">.002</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;52.6&#x000b1;2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;57.1&#x000b1;2.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;4.6&#x000b1;3.4</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.3, 2.1</td><td align="char" char="." rowspan="1" colspan="1">.179</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">R20</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;56.4&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;64.8&#x000b1;2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;8.4&#x000b1;3.9</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;16.2, &#x02212;0.7</td><td align="char" char="." rowspan="1" colspan="1">.034</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;55.1&#x000b1;2.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;63.8&#x000b1;2.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;8.7&#x000b1;3.3</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;15.3, &#x02212;2.0</td><td align="char" char="." rowspan="1" colspan="1">.011</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;34.4&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;43.8&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;9.5&#x000b1;2.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;13.5, &#x02212;5.5</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;32.8&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;38.4&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.6&#x000b1;1.4</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;8.3, &#x02212;2.8</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.9&#x000b1;3.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;21.9&#x000b1;3.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;10.0&#x000b1;5.1</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;20.1, 0.1</td><td align="char" char="." rowspan="1" colspan="1">.051</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.4&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;20.3&#x000b1;2.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;8.9&#x000b1;3.9</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;16.6, &#x02212;1.3</td><td align="char" char="." rowspan="1" colspan="1">.023</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.3&#x000b1;2.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9.0&#x000b1;2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;2.3&#x000b1;3.4</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;9.0, &#x02212;4.5</td><td align="char" char="." rowspan="1" colspan="1">.511</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.9&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.6&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.7&#x000b1;2.1</td><td align="char" char=" " rowspan="1" colspan="1">0.7, 8.7</td><td align="char" char="." rowspan="1" colspan="1">.022<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;46.6&#x000b1;1.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;58.3&#x000b1;1.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.7&#x000b1;2.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;16.7, &#x02212;6.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;45.2&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;53.2&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;8.0&#x000b1;1.8</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.5, &#x02212;4.4</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein B</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;42.3&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;53.2&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;10.9&#x000b1;2.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;15.1, &#x02212;6.6</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;42.4&#x000b1;1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;48.1&#x000b1;1.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.7&#x000b1;1.6</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;8.8, &#x02212;2.5</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein A1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.5&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.4&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;2.1&#x000b1;2.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;6.5, 2.3</td><td align="char" char="." rowspan="1" colspan="1">.346</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.7&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.9&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.2&#x000b1;1.4</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.5, 4.9</td><td align="char" char="." rowspan="1" colspan="1">.109<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipoprotein(a)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">29.0&#x000b1;11.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">41.2&#x000b1;11.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.3&#x000b1;16.1</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;19.6, 44.2</td><td align="char" char="." rowspan="1" colspan="1">.447</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15.1&#x000b1;4.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.9&#x000b1;3.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10.8&#x000b1;5.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.3, 22</td><td align="char" char="." rowspan="1" colspan="1">.057</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.9&#x000b1;3.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.8&#x000b1;3.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.9&#x000b1;4.8</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;6.6, 12.5</td><td align="char" char="." rowspan="1" colspan="1">.544</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.1&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;1.3&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;1.4&#x000b1;2.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;5.3, 2.5</td><td align="char" char="." rowspan="1" colspan="1">.479<xref ref-type="fn" rid="cdr12213-note-0008">b</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="cdr12213-note-0006"><p>Variables are presented as mean &#x000b1; SD or least&#x02010;squares means &#x000b1; SEM. SD, standard deviation; SEM, standard error of the mean; CI, confidence interval; R, rosuvastatin; E, ezetimibe; BMI, body mass index; LDL, low&#x02010;density lipoprotein; HDL, high&#x02010;density lipoprotein.</p></fn><fn id="cdr12213-note-0007"><label>a</label><p>Average doses of rosuvastatin in the pooled patients: R, 11.7&#x000a0;mg; R+E, 11.7&#x000a0;mg.</p></fn><fn id="cdr12213-note-0008"><label>b</label><p>
<italic>P</italic> value &#x0003c;.05 by ANCOVA between R+E in patients with diabetes vs R+E in nondiabetic patients.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="cdr12213-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Greater reduction in cholesterol observed in patients with DM than in non&#x02010;DM patients receiving combo therapy. Among patients receiving combo therapy, patients with DM exhibited greater reductions in cholesterol compared to non&#x02010;DM patients, whereas patients with DM and non&#x02010;DM patients receiving monotherapy showed comparable levels of cholesterol reduction. Bars represent standard errors; DM, diabetes mellitus; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; non&#x02010;HDL&#x02010;C, non&#x02010;high&#x02010;density lipoprotein cholesterol; Apo B, apolipoprotein B; TC, total cholesterol; R, rosuvastatin; E, ezetimibe. *<italic>P</italic>&#x0003c;.05 for the specified between&#x02010;treatment difference</p></caption><graphic id="nlm-graphic-7" xlink:href="CDR-34-371-g004"/></fig><p>In the 135 patients with MetS (33%), the difference in the efficacy between combo therapy and monotherapy was more pronounced than in non&#x02010;MetS patients (patients with MetS: &#x02212;63.9% vs &#x02212;47.6%, difference: &#x02212;16.3%, <italic>P</italic>&#x0003c;.001; non&#x02010;MetS patients: &#x02212;57.6% vs &#x02212;51.2%, difference: &#x02212;6.5%, <italic>P</italic>=.001 at week 8; Table&#x000a0;<xref rid="cdr12213-tbl-0004" ref-type="table-wrap">4</xref>, Figure&#x000a0;<xref rid="cdr12213-fig-0005" ref-type="fig">5</xref>). In other words, the potency of the combo therapy was greater in patients with MetS than in non&#x02010;MetS patients, whereas the potency of the monotherapy was similar between patients with MetS and non&#x02010;MetS patients (combo therapy: patients with MetS &#x02212;63.9% vs non&#x02010;MetS patients &#x02212;57.6%, <italic>P</italic>=.013). These results were also similar to those observed for other lipids, including total cholesterol, non&#x02010;HDL cholesterol, and apolipoprotein B (Table&#x000a0;<xref rid="cdr12213-tbl-0004" ref-type="table-wrap">4</xref>, Figure&#x000a0;<xref rid="cdr12213-fig-0005" ref-type="fig">5</xref>). Combo therapy was more potent than monotherapy in reducing the TG levels and in elevating the HDL cholesterol levels, both in patients with and without MetS (Figure S2). Interestingly, the potencies of both combo therapy and monotherapy on the TG and HDL cholesterol levels were greater in patients with MetS than in non&#x02010;MetS patients (Figure S2). No significant differences were observed in the apolipoprotein A levels (Table&#x000a0;<xref rid="cdr12213-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="cdr12213-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Percentage changes in lipid parameters from baseline to week 8 (full analysis set population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Metabolic syndrome</th><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Nonmetabolic syndrome</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">R(n=69)</th><th align="center" valign="top" rowspan="1" colspan="1">R+E(n=66)</th><th align="center" valign="top" rowspan="1" colspan="1">Difference</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI for difference</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">R(n=135)</th><th align="center" valign="top" rowspan="1" colspan="1">R+E(n=137)</th><th align="center" valign="top" rowspan="1" colspan="1">Difference</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI for difference</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="11" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.9&#x000b1;9.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.7&#x000b1;7.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.2&#x000b1;8.6</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.372</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63.9&#x000b1;9.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.0&#x000b1;8.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.1&#x000b1;8.6</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.960</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male, n (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38 (55.1)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">35 (53.0)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.925</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80 (59.3)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">78 (56.9)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.698</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.4&#x000b1;2.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.0&#x000b1;2.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.4&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.689</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.5&#x000b1;2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.2&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.3&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.341</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Average R dose, mg<xref ref-type="fn" rid="cdr12213-note-0010">a</xref>
</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.5&#x000b1;6.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.6&#x000b1;6.2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.8&#x000b1;6.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10.8&#x000b1;6.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Week 8</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">%&#x000b1;SEM</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b1;" rowspan="1" colspan="1">%&#x000b1;SEM</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;47.6&#x000b1;1.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;63.9&#x000b1;1.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;16.3&#x000b1;2.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;21.3, &#x02212;11.4</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;51.2&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;57.6&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.5&#x000b1;2.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;10.4, &#x02212;2.6</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="fn" rid="cdr12213-note-0011">b</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">R5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;39.0&#x000b1;3.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;54.9&#x000b1;4.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.80&#x000b1;6.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;28.0, &#x02212;3.6</td><td align="char" char="." rowspan="1" colspan="1">.013</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;44.1&#x000b1;2.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;55.7&#x000b1;2.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.6&#x000b1;3.1</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;17.7, 5.6</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">R10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;49.3&#x000b1;2.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;65.3&#x000b1;2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;16.0&#x000b1;3.6</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;23.2, &#x02212;8.8</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;53.9&#x000b1;2.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;56.0&#x000b1;2.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;2.1&#x000b1;3.3</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;8.7, 4,5</td><td align="char" char="." rowspan="1" colspan="1">.529<xref ref-type="fn" rid="cdr12213-note-0011">b</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">R20</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;55.1&#x000b1;2.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;66.6&#x000b1;1.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.5&#x000b1;2.9</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;17.3, &#x02212;5.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;55.3&#x000b1;2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;62.8&#x000b1;2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.5&#x000b1;3.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;14.9, &#x02212;0.1</td><td align="char" char="." rowspan="1" colspan="1">.046</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;33.5&#x000b1;1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;45.0&#x000b1;1.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.5&#x000b1;1.8</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;15.0, &#x02212;8.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;33.4&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;37.7&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;4.3&#x000b1;1.5</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;7.2, &#x02212;1.4</td><td align="char" char="." rowspan="1" colspan="1">.003</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;23.6&#x000b1;2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;38.5&#x000b1;2.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;14.9&#x000b1;3.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;22.3, &#x02212;7.5</td><td align="char" char="." rowspan="1" colspan="1">.051</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.9&#x000b1;3.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.8&#x000b1;2.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.9&#x000b1;4.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;14.1, 2.3</td><td align="char" char="." rowspan="1" colspan="1">.161</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15.6&#x000b1;2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.9&#x000b1;2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.3&#x000b1;3.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;3.0, 11.6</td><td align="char" char="." rowspan="1" colspan="1">.511</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.9&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.4&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.5&#x000b1;2.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;2.3, 5.4</td><td align="char" char="." rowspan="1" colspan="1">.437</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;HDL cholesterol</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;44.5&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;59.2&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;14.8&#x000b1;2.1</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;18.8, &#x02212;10.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;46.4&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;52.6&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.2&#x000b1;1.9</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;10.0, &#x02212;2.4</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="fn" rid="cdr12213-note-0011">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ApolipoproteinB</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;41.0&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;53.7&#x000b1;1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;12.7&#x000b1;2.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;16.7, &#x02212;8.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;43.1&#x000b1;1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;47.7&#x000b1;1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;4.6&#x000b1;1.7</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;7.9, &#x02212;1.4</td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="fn" rid="cdr12213-note-0011">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ApolipoproteinA1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.4&#x000b1;1.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.8&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.4&#x000b1;2.2</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;3.9, 4.7</td><td align="char" char="." rowspan="1" colspan="1">.855</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.7&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.9&#x000b1;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.2&#x000b1;1.4</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.6, 3.9</td><td align="char" char="." rowspan="1" colspan="1">.409</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipoprotein(a)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">17.3&#x000b1;8.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">41.1&#x000b1;8.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">23.8&#x000b1;11.5</td><td align="char" char=" " rowspan="1" colspan="1">1.1, 46.4</td><td align="char" char="." rowspan="1" colspan="1">.040</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">21.4&#x000b1;5.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.6&#x000b1;5.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.2&#x000b1;8.0</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.6, 19.9</td><td align="char" char="." rowspan="1" colspan="1">.603</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose, mg/dL</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.9&#x000b1;3.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.1&#x000b1;3.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;1.8&#x000b1;4.3</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;10.4, 6.8</td><td align="char" char="." rowspan="1" colspan="1">.676</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.5&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.4&#x000b1;1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.9&#x000b1;2.3</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;3.7, 5.4</td><td align="char" char="." rowspan="1" colspan="1">.713</td></tr></tbody></table><table-wrap-foot><fn id="cdr12213-note-0009"><p>Variables are presented as mean &#x000b1; SD or least&#x02010;squares means &#x000b1; SEM. SD, standard deviation; SEM, standard error of the mean; R, rosuvastatin; E, ezetimibe; BMI, body mass index; LDL, low&#x02010;density lipoprotein; HDL, high&#x02010;density lipoprotein.</p></fn><fn id="cdr12213-note-0010"><label>a</label><p>Average dose of rosuvastatin in the pooled patients: R, 11.7&#x000a0;mg; R+E, 11.7&#x000a0;mg.</p></fn><fn id="cdr12213-note-0011"><label>b</label><p>
<italic>P</italic> value &#x0003c;.05 by ANCOVA test between R+E in patients with metabolic syndrome vs R+E in nonmetabolic syndrome patients.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="cdr12213-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Greater reduction in cholesterol in patients with MetS vs non&#x02010;MetS patients receiving combo therapy. Among patients receiving combo therapy, patients with MetS showed greater reductions in cholesterol compared to non&#x02010;MetS patients, whereas comparable reductions in cholesterol were observed in patients with MetS vs non&#x02010;MetS patients receiving monotherapy. Bars represent standard errors; MetS, metabolic syndrome; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; non&#x02010;HDL&#x02010;C, non&#x02010;high&#x02010;density lipoprotein cholesterol; Apo B, apolipoprotein B; TC, total cholesterol; R, rosuvastatin; E, ezetimibe. *<italic>P</italic>&#x0003c;.05 for the specified between&#x02010;treatment difference</p></caption><graphic id="nlm-graphic-9" xlink:href="CDR-34-371-g005"/></fig><p>The target LDL achievement rate was higher in patients treated with combo therapy than in patients treated with monotherapy (Table&#x000a0;<xref rid="cdr12213-tbl-0005" ref-type="table-wrap">5</xref>). In the pooled data analysis, 367 patients (90.1%) achieved the prespecified goals of LDL cholesterol levels depending on CHD risk factors according to the ATP III guideline, and more patients treated with combo therapy achieved the LDL cholesterol targets when compared with patients treated with monotherapy (94.1% vs 86.3%, <italic>P</italic>=.009). Moreover, patients with CHD/CHD risk equivalents or a 10&#x02010;year risk &#x0003e;20% treated with combo therapy showed a higher achievement rate of the LDL cholesterol target than those treated with monotherapy (94.4% vs 84.7%, <italic>P</italic>=.003) (Table&#x000a0;<xref rid="cdr12213-tbl-0005" ref-type="table-wrap">5</xref>).</p><table-wrap id="cdr12213-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Proportion of subjects achieving low&#x02010;density lipoprotein cholesterol goals by cardiovascular risk category (full analysis set population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Rosuvastatin (n=204)</th><th align="center" valign="top" rowspan="1" colspan="1">Rosuvastatin + ezetimibe(n=203)</th><th align="center" valign="top" rowspan="1" colspan="1">R5 (n=68)</th><th align="center" valign="top" rowspan="1" colspan="1">R5+E10 (n=67)</th><th align="center" valign="top" rowspan="1" colspan="1">R10 (n=67)</th><th align="center" valign="top" rowspan="1" colspan="1">R10+E10 (n=68)</th><th align="center" valign="top" rowspan="1" colspan="1">R20 (n=69)</th><th align="center" valign="top" rowspan="1" colspan="1">R20+E10 (n=68)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total patients achieving LDL cholesterol goal, n (%)</td><td align="char" char=" " rowspan="1" colspan="1">176 (86.3)</td><td align="char" char=" " rowspan="1" colspan="1">191 (94.1)<xref ref-type="fn" rid="cdr12213-note-0013">a</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">50 (73.5)</td><td align="char" char=" " rowspan="1" colspan="1">65 (97.0)<xref ref-type="fn" rid="cdr12213-note-0013">a</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">63 (94.0)</td><td align="char" char=" " rowspan="1" colspan="1">62 (91.2)</td><td align="char" char=" " rowspan="1" colspan="1">63 (91.3)</td><td align="char" char=" " rowspan="1" colspan="1">64 (94.1)</td></tr><tr><td align="char" char=" " colspan="9" rowspan="1">Patients by CHD risk factors, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Risk factors 0&#x02013;1</td><td align="char" char=" " rowspan="1" colspan="1">11 (100)</td><td align="char" char=" " rowspan="1" colspan="1">12 (92.3)</td><td align="char" char=" " rowspan="1" colspan="1">4 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (75.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Risk factors &#x02265;2&#x02010; and 10&#x02010;y risk &#x02264;20%</td><td align="char" char=" " rowspan="1" colspan="1">10 (100)</td><td align="char" char=" " rowspan="1" colspan="1">10 (90.9)</td><td align="char" char=" " rowspan="1" colspan="1">3 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (100.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CHD/CHD risk equivalents or 10&#x02010;y risk &#x0003e;20%</td><td align="char" char=" " rowspan="1" colspan="1">155 (84.7)</td><td align="char" char=" " rowspan="1" colspan="1">169 (94.4)<xref ref-type="fn" rid="cdr12213-note-0014">b</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">43 (70.5)</td><td align="char" char=" " rowspan="1" colspan="1">57 (96.6) <xref ref-type="fn" rid="cdr12213-note-0014">b</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">56 (93.3)</td><td align="char" char=" " rowspan="1" colspan="1">55 (91.7)</td><td align="char" char=" " rowspan="1" colspan="1">56 (90.3)</td><td align="char" char=" " rowspan="1" colspan="1">57 (95.0)</td></tr></tbody></table><table-wrap-foot><fn id="cdr12213-note-0012"><p>LDL, low&#x02010;density lipoprotein; CHD, coronary heart disease; R, rosuvastatin; E, ezetimibe.</p></fn><fn id="cdr12213-note-0013"><label>a</label><p>
<italic>P</italic> value &#x0003c;.05 by the Cochran&#x02013;Mantel&#x02013;Haenszel test, with the CHD risk factors defined according to the National Cholesterol Education Program Adult Treatment Panel III.</p></fn><fn id="cdr12213-note-0014"><label>b</label><p>
<italic>P</italic> value &#x0003c;.05 by Pearson's chi&#x02010;square test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cdr12213-sec-0013"><label>3.3</label><title>Safety</title><p>No serious drug&#x02010;related adverse events (AEs) were reported. There were three serious AEs, including one in the monotherapy group (breast cancer) and two in the combo therapy group (left ulnar fracture and epigastric pain), although these were not considered drug&#x02010;related AEs by the investigators. The incidence of prespecified AEs was generally comparable between the two groups, with no clinically meaningful differences or statistical significance (Table S1). Consecutive elevations &#x02265;3 times the upper normal limits in alanine aminotransferase or aspartate aminotransferase occurred in 1 (0.5%) of 204 patients receiving monotherapy and 1 (0.5%) of 206 patients receiving combo therapy. Elevations &#x02265;5 times the upper normal limits in creatine kinase occurred only in 1 (0.5%) of 204 patients receiving combo therapy, with no significant differences between the groups.</p></sec></sec><sec id="cdr12213-sec-0014"><label>4</label><title>Discussion</title><p>This study sought to evaluate the effects of fixed&#x02010;dose combination of rosuvastatin and ezetimibe compared to rosuvastatin alone in the treatment for primary hypercholesterolemia patients with LDL cholesterol levels above the ATP III recommended treatment targets. To our knowledge, the MRS&#x02010;ROZE study is the first trial evaluating the safety and efficacy of fixed&#x02010;dose combinations of rosuvastatin and ezetimibe in subjects with hypercholesterolemia.</p><p>The reduction in LDL cholesterol by fixed&#x02010;dose combination therapy was significantly greater than that of rosuvastatin monotherapy in the pooled group, as well as in the subgroup comparisons for each rosuvastatin dose, at both weeks 4 and 8. Combo therapy produced an additional significant reduction in the baseline LDL cholesterol of 9.7%. Moreover, significantly more subjects reached the ATP III LDL cholesterol goals with combo therapy compared with monotherapy, and combo therapy resulted in significantly greater reductions in the total cholesterol, TG, non&#x02010;HDL cholesterol, and apolipoprotein B levels, as early as after 4 or 8 weeks. The changes in HDL cholesterol also tended to be greater by combo therapy than by monotherapy, although this did not reach statistical significance.</p><p>The reductions in LDL cholesterol were 43%, 52%, and 54% by rosuvastatin 5, 10, and 20&#x000a0;mg, respectively. Specifically, the reduction in LDL cholesterol in our study with rosuvastatin 10&#x000a0;mg was 52%, which is relatively higher than in previous studies that mainly evaluated Western populations: 44.6% to 47%.<xref rid="cdr12213-bib-0025" ref-type="ref">25</xref>, <xref rid="cdr12213-bib-0026" ref-type="ref">26</xref>, <xref rid="cdr12213-bib-0027" ref-type="ref">27</xref> Although previous large&#x02010;scale clinical trials have consistently demonstrated the statin efficacy and safety in a variety of populations, few clinical trials have examined the efficacy of statins in different ethnic and racial groups; especially, on the basis of Asian ethnicity, most studies have been carried out in Asia.<xref rid="cdr12213-bib-0028" ref-type="ref">28</xref> A few previous studies evaluated the effect of rosuvastatin in Japanese population. The reductions in LDL cholesterol with rosuvastatin 10&#x000a0;mg in these studies were 49.7% <xref rid="cdr12213-bib-0029" ref-type="ref">29</xref> and 49.2%,<xref rid="cdr12213-bib-0030" ref-type="ref">30</xref> which were comparable to our result (52%) and also higher than the results of Western populations. Liao described that genetically based differences at the level of drug transporters and hepatic enzymes in the metabolism of statins would be the potential mechanisms of enhanced response to statins in Asians.<xref rid="cdr12213-bib-0028" ref-type="ref">28</xref>
</p><p>The incremental reduction in LDL cholesterol by ezetimibe in our study was 9.7%. Previous studies reported the reduction in LDL cholesterol differed according to the study design. Previous factorial studies reported the incremental reduction in LDL cholesterol with the addition of ezetimibe: 12.1% &#x02013; 13.8%.<xref rid="cdr12213-bib-0010" ref-type="ref">10</xref>, <xref rid="cdr12213-bib-0013" ref-type="ref">13</xref>, <xref rid="cdr12213-bib-0020" ref-type="ref">20</xref> Moreover, previous add&#x02010;on studies reported higher incremental reduction in LDL cholesterol: 18.2 &#x02013; 25.2%.<xref rid="cdr12213-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="cdr12213-bib-0031" ref-type="ref">
<sup>31</sup>
</xref>, <xref rid="cdr12213-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> The differences in baseline LDL cholesterol levels that might be affected by previously receiving statin therapy in add&#x02010;on studies might explain the difference. The present study is a factorial study that compared the efficacy of combo therapy vs monotherapy after 4&#x000a0;weeks of therapeutic lifestyle changes and washout period. Based on this information, the incremental LDL cholesterol of 9.7% was comparable to previous results.</p><p>In our study, the efficacy of combo therapy in comparison with monotherapy on lowering LDL cholesterol was even greater in patients with DM than in non&#x02010;DM patients. Diabetes has been listed as a CHD risk equivalent by ATP III.<xref rid="cdr12213-bib-0022" ref-type="ref">22</xref> Therefore, the LDL cholesterol goal for patients with diabetes is equivalent to that of patients with known CHD.<xref rid="cdr12213-bib-0002" ref-type="ref">2</xref> Previous studies have reported the improved effects of adding ezetimibe to simvastatin or rosuvastatin compared to statin monotherapy in patients with DM.<xref rid="cdr12213-bib-0033" ref-type="ref">33</xref>, <xref rid="cdr12213-bib-0034" ref-type="ref">34</xref>, <xref rid="cdr12213-bib-0035" ref-type="ref">35</xref>, <xref rid="cdr12213-bib-0036" ref-type="ref">36</xref> In our study, we reproduced these phenomena using fixed&#x02010;dose combinations of ezetimibe and rosuvastatin in patients with DM. Patients with DM have a unique pathophysiology in terms of the intestinal cholesterol absorption. They have higher expression of the NPC1L1 gene, which facilitates the cholesterol absorption in the small intestine,<xref rid="cdr12213-bib-0036" ref-type="ref">36</xref>, <xref rid="cdr12213-bib-0037" ref-type="ref">37</xref> while they have lower expression of ATP&#x02010;binding cassette transporters G5 and G8, which normally facilitate the excretion of cholesterol from the intestinal epithelial cells to the small bowel lumen,<xref rid="cdr12213-bib-0038" ref-type="ref">38</xref> resulting in an enhanced cholesterol absorption. Ezetimibe selectively inhibits cholesterol absorption from the intestine by binding to the NPC1L1 receptor. Therefore, combo therapy with ezetimibe might be more effective in patients with DM.</p><p>In addition, in our study, the potency of combo therapy was found to be more effective in patients with MetS compared with non&#x02010;MetS patients. Previous studies have reported that the combination of ezetimibe with a statin produced a greater reduction in LDL cholesterol in patients with MetS,<xref rid="cdr12213-bib-0039" ref-type="ref">39</xref>, <xref rid="cdr12213-bib-0040" ref-type="ref">40</xref> especially for simvastatin.<xref rid="cdr12213-bib-0041" ref-type="ref">41</xref>, <xref rid="cdr12213-bib-0042" ref-type="ref">42</xref> In this study using fixed&#x02010;dose combinations, we confirmed that combo therapy is useful for patients with MetS, similar to patients with DM.</p><p>The results of other lipids, including total cholesterol, non&#x02010;HDL cholesterol, and apolipoprotein B, also revealed that the differences in efficacy of combo therapy compared with monotherapy were more effective in patients with DM or MetS than in those without.</p><p>The safety and tolerability profiles observed in this study were generally comparable between the two groups and to those of previous studies of ezetimibe and rosuvastatin of similar duration. No drug&#x02010;related serious AEs were observed, and the incidence of muscle, liver, hepatitis&#x02010;related, gastrointestinal&#x02010;related, and allergic AEs was generally low and comparable between the two treatment groups and with other previous studies. However, although the results of this study showed comparative safety and efficacy of fixed&#x02010;dose combination of rosuvastatin and ezetimibe vs rosuvastatin alone, the duration of the study was relatively short, limiting the ability to generalize these results to longer&#x02010;term therapy.</p><p>In conclusion, the results of this study support the safety and efficacy of fixed&#x02010;dose combination of rosuvastatin (5, 10, or 20&#x000a0;mg) and ezetimibe (10&#x000a0;mg) compared with rosuvastatin alone in patients with hypercholesterolemia. The benefits of fixed&#x02010;dose combination treatment were more pronounced in DM and MetS patients.</p></sec><sec id="cdr12213-sec-0016"><title>Funding</title><p>This study was funded by the Ministry of Health and Welfare (MHW) through the Korea Health Industry Development Institute (KHIDI), Korea Health Technology R&#x00026;D Project (HI14C1277).</p></sec><sec id="cdr12213-sec-0017"><title>Conflict of Interest</title><p>The authors declare no conflict of interest.</p></sec><sec id="cdr12213-sec-0018"><title>Ethics</title><p>This study was approved by Seoul National University Hospital Institutional Review Board (date of approval: July 31, 2014).</p></sec><sec id="cdr12213-sec-0019"><title>Author Contributions</title><p>KJK, SHK, IHC, and HSK were involved in the conception and design of the study. All the authors were involved in the analysis or interpretation of data. KJK, SHK, IHC, and HSK were involved in the drafting of the manuscript. All the authors were involved in the critical review and revision of the manuscript. All the authors approved the final version of the manuscript, including the authorship list.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cdr12213-sup-0001"><caption><p>&#x000a0;</p></caption><media xlink:href="CDR-34-371-s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cdr12213-sup-0002"><caption><p>&#x000a0;</p></caption><media xlink:href="CDR-34-371-s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cdr12213-sup-0003"><caption><p>&#x000a0;</p></caption><media xlink:href="CDR-34-371-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cdr12213-sec-0015"><title>Acknowledgments</title><p>The contributions of the MRS&#x02010;ROZE study investigators and Hanmi Corporation are gratefully acknowledged.</p></ack><ref-list content-type="cited-references" id="cdr12213-bibl-0001"><title>References</title><ref id="cdr12213-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cdr12213-cit-0001">
<collab collab-type="authors">National Cholesterol Education Program Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</collab>
. <article-title>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>:<fpage>3143</fpage>&#x02013;<lpage>3421</lpage>.<pub-id pub-id-type="pmid">12485966</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cdr12213-cit-0002">
<string-name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Cleeman</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Merz</surname>
<given-names>CN</given-names>
</string-name>, et&#x000a0;al. <article-title>Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>:<fpage>227</fpage>&#x02013;<lpage>239</lpage>.<pub-id pub-id-type="pmid">15249516</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cdr12213-cit-0003">
<string-name>
<surname>Smith</surname>
<given-names>MEB</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Haney</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Carson</surname>
<given-names>S</given-names>
</string-name>. <article-title>Drug class review: HMG&#x02010;CoA reductase inhibitors (statins)</article-title>. <source>Drug Class Review</source>. <year>2009</year> [Internet]. Update 5. <ext-link ext-link-type="uri" xlink:href="http://www.ohsu.edu/drugeffectiveness/reports/final.cfm">http://www.ohsu.edu/drugeffectiveness/reports/final.cfm</ext-link>. Accessed November 1, 2015.</mixed-citation></ref><ref id="cdr12213-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cdr12213-cit-0004">
<collab collab-type="authors">Heart Protection Study Collaborative Group</collab>
. <article-title>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high&#x02010;risk individuals: a randomised placebo&#x02010;controlled trial</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>360</volume>:<fpage>7</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">12114036</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cdr12213-cit-0005">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>McCabe</surname>
<given-names>CH</given-names>
</string-name>, et&#x000a0;al. <article-title>Intensive versus moderate lipid lowering with statins after acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>:<fpage>1495</fpage>&#x02013;<lpage>1504</lpage>.<pub-id pub-id-type="pmid">15007110</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cdr12213-cit-0006">
<string-name>
<surname>LaRosa</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Waters</surname>
<given-names>DD</given-names>
</string-name>, et&#x000a0;al. <article-title>Intensive lipid lowering with atorvastatin in patients with stable coronary disease</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>1425</fpage>&#x02013;<lpage>1435</lpage>.<pub-id pub-id-type="pmid">15755765</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cdr12213-cit-0007">
<string-name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Faergeman</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>, et&#x000a0;al. <article-title>High&#x02010;dose atorvastatin vs usual&#x02010;dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>294</volume>:<fpage>2437</fpage>&#x02013;<lpage>2445</lpage>.<pub-id pub-id-type="pmid">16287954</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cdr12213-cit-0008">
<string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Akdim</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Stroes</surname>
<given-names>ES</given-names>
</string-name>, et&#x000a0;al. <article-title>Simvastatin with or without ezetimibe in familial hypercholesterolemia</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>:<fpage>1431</fpage>&#x02013;<lpage>1443</lpage>.<pub-id pub-id-type="pmid">18376000</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cdr12213-cit-0009">
<string-name>
<surname>Pearson</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Laurora</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kafonek</surname>
<given-names>S</given-names>
</string-name>. <article-title>The lipid treatment assessment project (L&#x02010;TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid&#x02010;lowering therapy and achieving low&#x02010;density lipoprotein cholesterol goals</article-title>. <source>Arch Intern Med</source>. <year>2000</year>;<volume>160</volume>:<fpage>459</fpage>&#x02013;<lpage>467</lpage>.<pub-id pub-id-type="pmid">10695686</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cdr12213-cit-0010">
<string-name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Houri</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Notarbartolo</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double&#x02010;blind trial</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>2409</fpage>&#x02013;<lpage>2415</lpage>.<pub-id pub-id-type="pmid">12719279</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cdr12213-cit-0011">
<string-name>
<surname>Armitage</surname>
<given-names>J</given-names>
</string-name>. <article-title>The safety of statins in clinical practice</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>:<fpage>1781</fpage>&#x02013;<lpage>1790</lpage>.<pub-id pub-id-type="pmid">17559928</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cdr12213-cit-0012">
<string-name>
<surname>Hamilton&#x02010;Craig</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kostner</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Colquhoun</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Woodhouse</surname>
<given-names>S</given-names>
</string-name>. <article-title>Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia</article-title>. <source>Vasc Health Risk Manag</source>. <year>2010</year>;<volume>6</volume>:<fpage>1023</fpage>&#x02013;<lpage>1037</lpage>.<pub-id pub-id-type="pmid">21127699</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cdr12213-cit-0013">
<string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>McGarry</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bettis</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>:<fpage>2125</fpage>&#x02013;<lpage>2134</lpage>.<pub-id pub-id-type="pmid">12505224</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cdr12213-cit-0014">
<string-name>
<surname>Van Heek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>France</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Compton</surname>
<given-names>DS</given-names>
</string-name>, et&#x000a0;al. <article-title>In vivo metabolism&#x02010;based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1997</year>;<volume>283</volume>:<fpage>157</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">9336320</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cdr12213-cit-0015">
<string-name>
<surname>Davis</surname>
<given-names>HR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Hoos</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Tetzloff</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Deficiency of Niemann&#x02010;Pick C1 Like 1 prevents atherosclerosis in ApoE&#x02010;/&#x02010; mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2007</year>;<volume>27</volume>:<fpage>841</fpage>&#x02013;<lpage>849</lpage>.<pub-id pub-id-type="pmid">17218600</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cdr12213-cit-0016">
<string-name>
<surname>Altmann</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>HR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>LJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Niemann&#x02010;Pick C1 Like 1 protein is critical for intestinal cholesterol absorption</article-title>. <source>Science</source>. <year>2004</year>;<volume>303</volume>:<fpage>1201</fpage>&#x02013;<lpage>1204</lpage>.<pub-id pub-id-type="pmid">14976318</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cdr12213-cit-0017">
<string-name>
<surname>Betters</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>. <article-title>NPC1L1 and cholesterol transport</article-title>. <source>FEBS Lett</source>. <year>2010</year>;<volume>584</volume>:<fpage>2740</fpage>&#x02013;<lpage>2747</lpage>.<pub-id pub-id-type="pmid">20307540</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cdr12213-cit-0018">
<string-name>
<surname>Huff</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Pollex</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</string-name>. <article-title>NPC1L1: evolution from pharmacological target to physiological sterol transporter</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2006</year>;<volume>26</volume>:<fpage>2433</fpage>&#x02013;<lpage>2438</lpage>.<pub-id pub-id-type="pmid">16973966</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cdr12213-cit-0019">
<string-name>
<surname>Bays</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Massaad</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up&#x02010;titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>108</volume>:<fpage>523</fpage>&#x02013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">21596364</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cdr12213-cit-0020">
<string-name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moccetti</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>:<fpage>673</fpage>&#x02013;<lpage>680</lpage>.<pub-id pub-id-type="pmid">17317370</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cdr12213-cit-0021">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, et&#x000a0;al. <article-title>Ezetimibe added to statin therapy after acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>:<fpage>2387</fpage>&#x02013;<lpage>2397</lpage>.<pub-id pub-id-type="pmid">26039521</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cdr12213-cit-0022">
<collab collab-type="authors">Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults</collab>
. <article-title>Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>285</volume>:<fpage>2486</fpage>&#x02013;<lpage>2497</lpage>.<pub-id pub-id-type="pmid">11368702</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cdr12213-cit-0023">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes&#x02013;2014</article-title>. <source>Diabetes Care</source>. <year>2014</year>;<volume>37</volume>(<issue>Suppl 1</issue>):<fpage>S14</fpage>&#x02013;<lpage>S80</lpage>.<pub-id pub-id-type="pmid">24357209</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cdr12213-cit-0024">
<string-name>
<surname>Alberti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Eckel</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</string-name>, et&#x000a0;al. <article-title>Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>1640</fpage>&#x02013;<lpage>1645</lpage>.<pub-id pub-id-type="pmid">19805654</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cdr12213-cit-0025">
<string-name>
<surname>Jones</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>EA</given-names>
</string-name>, et&#x000a0;al. <article-title>Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>92</volume>:<fpage>152</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">12860216</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cdr12213-cit-0026">
<string-name>
<surname>Schuster</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Barter</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Stender</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study</article-title>. <source>Am Heart J</source>. <year>2004</year>;<volume>147</volume>:<fpage>705</fpage>&#x02013;<lpage>713</lpage>.<pub-id pub-id-type="pmid">15077101</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cdr12213-cit-0027">
<string-name>
<surname>Clearfield</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Amerena</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bassand</surname>
<given-names>JP</given-names>
</string-name>, et&#x000a0;al. <article-title>Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high&#x02010;risk patients with hypercholesterolemia&#x02013;Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)</article-title>. <source>Trials</source>. <year>2006</year>;<volume>7</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">17184550</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cdr12213-cit-0028">
<string-name>
<surname>Liao</surname>
<given-names>JK</given-names>
</string-name>. <article-title>Safety and efficacy of statins in Asians</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>:<fpage>410</fpage>&#x02013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">17261409</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cdr12213-cit-0029">
<string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dane</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Strutt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Raza</surname>
<given-names>A</given-names>
</string-name>. <article-title>Randomized dose&#x02010;response study of rosuvastatin in Japanese patients with hypercholesterolemia</article-title>. <source>J Atheroscler Thromb</source>. <year>2003</year>;<volume>10</volume>:<fpage>329</fpage>&#x02013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">15037821</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cdr12213-cit-0030">
<string-name>
<surname>Mabuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nohara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Higashikata</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia</article-title>. <source>J Atheroscler Thromb</source>. <year>2004</year>;<volume>11</volume>:<fpage>152</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">15256766</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cdr12213-cit-0031">
<string-name>
<surname>Farnier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Volpe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Massaad</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>C</given-names>
</string-name>. <article-title>Effect of co&#x02010;administering ezetimibe with on&#x02010;going simvastatin treatment on LDL&#x02010;C goal attainment in hypercholesterolemic patients with coronary heart disease</article-title>. <source>Int J Cardiol</source>. <year>2005</year>;<volume>10</volume>:<fpage>327</fpage>&#x02013;<lpage>332</lpage>.</mixed-citation></ref><ref id="cdr12213-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cdr12213-cit-0032">
<string-name>
<surname>Gagne</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bays</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>SR</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia</article-title>. <source>Am J Cardiol</source>. <year>2002</year>;<volume>90</volume>:<fpage>1084</fpage>&#x02013;<lpage>1091</lpage>.<pub-id pub-id-type="pmid">12423708</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cdr12213-cit-0033">
<string-name>
<surname>Chang</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>CH</given-names>
</string-name>, et&#x000a0;al. <article-title>Simvastatin&#x02010;ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population&#x02010;based dynamic cohort study</article-title>. <source>Int J Cardiol</source>. <year>2015</year>;<volume>190</volume>:<fpage>20</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">25912112</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cdr12213-cit-0034">
<string-name>
<surname>Rosen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Jimenez</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Pirags</surname>
<given-names>V</given-names>
</string-name>, et&#x000a0;al. <article-title>A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid&#x02010;lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease</article-title>. <source>Diab Vasc Dis Res</source>. <year>2013</year>;<volume>10</volume>:<fpage>277</fpage>&#x02013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">23288881</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cdr12213-cit-0035">
<string-name>
<surname>Ruggenenti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cattaneo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rota</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Effects of combined ezetimibe and simvastatin therapy as compared with Simvastatin alone in patients with type 2 diabetes a prospective randomized double&#x02010;blind clinical trial</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>:<fpage>1954</fpage>&#x02013;<lpage>1956</lpage>.<pub-id pub-id-type="pmid">20566677</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cdr12213-cit-0036">
<string-name>
<surname>Torimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Okada</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes</article-title>. <source>Lipids Health Dis</source>. <year>2013</year>;<volume>12</volume>:<fpage>137</fpage>.<pub-id pub-id-type="pmid">24053480</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cdr12213-cit-0037">
<string-name>
<surname>Ravid</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Bendayan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Delvin</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2008</year>;<volume>295</volume>:<fpage>G873</fpage>&#x02013;<lpage>G885</lpage>.<pub-id pub-id-type="pmid">18772361</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cdr12213-cit-0038">
<string-name>
<surname>Lally</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Owens</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tomkin</surname>
<given-names>GH</given-names>
</string-name>. <article-title>Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non&#x02010;diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann&#x02010;Pick C1&#x02010;like 1 mRNA</article-title>. <source>Diabetologia</source>. <year>2007</year>;<volume>50</volume>:<fpage>217</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">17102949</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cdr12213-cit-0039">
<string-name>
<surname>Denke</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pearson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>McBride</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gazzara</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Tershakovec</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Ezetimibe added to ongoing statin therapy improves LDL&#x02010;C goal attainment and lipid profile in patients with diabetes or metabolic syndrome</article-title>. <source>Diab Vasc Dis Res</source>. <year>2006</year>;<volume>3</volume>:<fpage>93</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">17058629</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cdr12213-cit-0040">
<string-name>
<surname>Simons</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tonkon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Masana</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Effects of ezetimibe added to on&#x02010;going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome</article-title>. <source>Curr Med Res Opin</source>. <year>2004</year>;<volume>20</volume>:<fpage>1437</fpage>&#x02013;<lpage>1445</lpage>.<pub-id pub-id-type="pmid">15383192</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cdr12213-cit-0041">
<string-name>
<surname>Rosen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Hsueh</surname>
<given-names>WA</given-names>
</string-name>, et&#x000a0;al. <article-title>Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk</article-title>. <source>Lipids Health Dis</source>. <year>2015</year>;<volume>14</volume>:<fpage>103</fpage>.<pub-id pub-id-type="pmid">26336957</pub-id></mixed-citation></ref><ref id="cdr12213-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cdr12213-cit-0042">
<string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</string-name>, et&#x000a0;al. <article-title>Lipid&#x02010;altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)</article-title>. <source>Am J Cardiol</source>. <year>2009</year>;<volume>103</volume>:<fpage>1694</fpage>&#x02013;<lpage>1702</lpage>.<pub-id pub-id-type="pmid">19539078</pub-id></mixed-citation></ref></ref-list></back></article>